return to take stock of the situation by circumventing events that will inevitably mature from today to the end of May 2018. the reasoning is focused solely on details and certain events to be discounted in this time range, therefore without any personal assumptions and ergo :
It is certain that by the end of April the company will publish the annual report to shareholders revealing numbers, positions and related updates; after twenty working days from the publication of the annual report by rule there will necessarily be the AGM where the company will inevitably update the shareholders substantially on the progress made by the October FDA announcement to date.
the crucial particularity and on which the evolution of the market rests in complement to these events, are always the interests of the managers and their options to be discounted in ordinary shares. I briefly recall the constraints that allow maturation:
- employee or director of the company for at least 3 years from the issuance of the options.
-progress of at least one of the studies in phase 2b or 3 already authorized for a start by a national regulatory body (in our case we refer to the FDA ok already matured in last October).
-conclusion of a partnership transaction or material license.
two of these points are practically already realized; the third point to be defined is the green disk for assigning options. the options in question are 2.5 million of which 1 million await the constraint of 7 May 2018 as a mandatory deadline to be met, after which all 2.5 million have matured, but not in full since 50% of the same will also comply with a constraint that provides that the price on the market at that date (for a good portion is 7 May 2018) must be equal to or higher than $ 3.22 AU for at least 30 continuous trading days.
this explains the first attempts recently recorded to raise the price to a higher level given the approach day after day of the events mentioned.
it seems natural that it is obvious that by May and for at least a month to follow the Neuren title we should appreciate about 10% to satisfy the first interests in the field, that is those of the managers and managers of the company.
I hope I was clear
Hello
Add to My Watchlist
What is My Watchlist?
